Senseonics Holdings Inc (NYSEAMERICAN:SENS) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 35,100,000 shares, a decline of 9.1% from the January 15th total of 38,630,000 shares. Based on an average daily trading volume, of 1,480,000 shares, the short-interest ratio is currently 23.7 days. Approximately 31.2% of the shares of the company are short sold.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC lifted its position in Senseonics by 194.0% in the third quarter. Commonwealth Equity Services LLC now owns 29,664 shares of the company’s stock worth $29,000 after purchasing an additional 19,574 shares during the period. Citigroup Inc. increased its holdings in shares of Senseonics by 130.4% in the fourth quarter. Citigroup Inc. now owns 38,446 shares of the company’s stock valued at $35,000 after buying an additional 21,761 shares in the last quarter. Trust Co. of Oklahoma bought a new position in shares of Senseonics in the fourth quarter valued at $46,000. Royal Bank of Canada increased its holdings in shares of Senseonics by 596.9% in the second quarter. Royal Bank of Canada now owns 29,269 shares of the company’s stock valued at $60,000 after buying an additional 25,069 shares in the last quarter. Finally, Palisade Capital Management LLC NJ increased its holdings in shares of Senseonics by 201.6% in the fourth quarter. Palisade Capital Management LLC NJ now owns 75,400 shares of the company’s stock valued at $69,000 after buying an additional 50,400 shares in the last quarter. Hedge funds and other institutional investors own 30.66% of the company’s stock.
Several equities analysts have recently issued reports on the company. Stifel Nicolaus assumed coverage on Senseonics in a research report on Tuesday, October 22nd. They set a “buy” rating and a $2.00 price objective for the company. Canaccord Genuity downgraded Senseonics from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $2.00 to $1.00 in a research report on Wednesday, November 13th. Finally, Craig Hallum downgraded Senseonics from a “buy” rating to a “hold” rating and set a $2.50 price objective for the company. in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $1.90.
SENS opened at $1.09 on Friday. Senseonics has a 1-year low of $0.80 and a 1-year high of $3.37. The business has a 50 day moving average price of $1.07.
Senseonics (NYSEAMERICAN:SENS) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.16). The firm had revenue of $4.32 million during the quarter, compared to analyst estimates of $6.18 million.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Further Reading: Balance Sheet
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.